Cited 8 times in
C/EBP binding activity to site F of the rat GLUT2 glucose transporter gene promoter is attenuated by c-Jun in vitro
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김재우 | - |
dc.date.accessioned | 2016-05-16T11:26:51Z | - |
dc.date.available | 2016-05-16T11:26:51Z | - |
dc.date.issued | 2002 | - |
dc.identifier.issn | 1226-3613 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/144570 | - |
dc.description.abstract | Telomeres are the ends of the linear chromosomes of eukaryotes and consist of tandem GT-rich repeats in telomere sequence i.e. 500-3000 repeats of 5'-TTAGGG-3' in human somatic cells, which are shortened gradually with age. The G-rich overhang of telomere sequence can adopt different intramolecular fold-backs and tetra-stranded DNA structures, in vitro, which inhibit telomerase activity. In this report, DNA binding agents to telomere sequence were studied novel therapeutic possibility to destabilize telomeric DNA sequences. Oligonucleotides containing the guanine repeats in human telomere sequence were synthesized and used for screening potential antitumor drugs. Telomeric DNA sequence was characterized using spectral measurements and CD spectroscopy. CD spectrum indicated that the double-stranded telomeric DNA is in a right-handed conformation. Polyacrylamide gel electrophoresis was performed for binding behaviors of antitumor compounds with telomeric DNA sequence. Drugs interacted with DNA sequence caused changes in the electrophoretic mobility and band intensity of the gels. Depending on the binding mode of the anticancer drugs, telomeric DNA sequence was differently recognized and the efficiency of cleavage of DNA varies in the bleomycin-treated samples under different conditions. DNA cleavage occurred at about 1% by the increments of 1 µM bleomycin-Fe(III). These results imply that the stability of human telomere sequence is important in conjunction with the cancer treatment and aging process. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 379~384 | - |
dc.relation.isPartOf | EXPERIMENTAL AND MOLECULAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Base Sequence | - |
dc.subject.MESH | Binding Sites | - |
dc.subject.MESH | CCAAT-Enhancer-Binding Proteins/metabolism* | - |
dc.subject.MESH | Cell Nucleus/metabolism | - |
dc.subject.MESH | Cells, Cultured | - |
dc.subject.MESH | Glucose Transporter Type 2 | - |
dc.subject.MESH | Liver/cytology | - |
dc.subject.MESH | Liver/metabolism | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Molecular Sequence Data | - |
dc.subject.MESH | Monosaccharide Transport Proteins/genetics* | - |
dc.subject.MESH | Monosaccharide Transport Proteins/metabolism | - |
dc.subject.MESH | Promoter Regions, Genetic/physiology* | - |
dc.subject.MESH | Proto-Oncogene Proteins c-jun/genetics | - |
dc.subject.MESH | Proto-Oncogene Proteins c-jun/metabolism* | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Recombinant Proteins/genetics | - |
dc.subject.MESH | Recombinant Proteins/metabolism | - |
dc.subject.MESH | Transcription Factor AP-1/genetics | - |
dc.subject.MESH | Transcription Factor AP-1/metabolism | - |
dc.title | C/EBP binding activity to site F of the rat GLUT2 glucose transporter gene promoter is attenuated by c-Jun in vitro | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Biochemistry & Molecular Biology (생화학,분자생물학) | - |
dc.contributor.googleauthor | Dongchul Suh | - |
dc.contributor.googleauthor | Yu Kyoung Oh | - |
dc.contributor.googleauthor | ByungChan Ahn | - |
dc.contributor.googleauthor | Man Wook Hur | - |
dc.contributor.googleauthor | Hye Ja Kim | - |
dc.contributor.googleauthor | Mi Hyoung Lee | - |
dc.contributor.googleauthor | Hyo Soon Joo | - |
dc.contributor.googleauthor | Chung Kyoon Auh | - |
dc.identifier.doi | 10.1038/emm.2002.46 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00865 | - |
dc.relation.journalcode | J00860 | - |
dc.identifier.eissn | 2092-6413 | - |
dc.identifier.pmid | 12526103 | - |
dc.subject.keyword | antitumor drugs | - |
dc.subject.keyword | bleomycin | - |
dc.subject.keyword | DNA damage | - |
dc.subject.keyword | gel mobility | - |
dc.subject.keyword | telomere DNA | - |
dc.contributor.alternativeName | Kim, Jae Woo | - |
dc.contributor.affiliatedAuthor | Kim, Jae Woo | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 34 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 379 | - |
dc.citation.endPage | 384 | - |
dc.identifier.bibliographicCitation | EXPERIMENTAL AND MOLECULAR MEDICINE, Vol.34(5) : 379-384, 2002 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.